As a leading annuity provider we recognised the need for an independent source to provide much needed guidance on the actual impact of the various scientific developments affecting life expectancy. There are major advancements being made in the identification and cure of many medical illnesses such as cancer, cardio-vascular and respiratory disease, which is improving how much longer we will live. However, the growth in lifestyle related problems such as diabetes is also reducing life expectancy. The establishment of the Longevity Science Advisory Panel will help us draw together an increased understanding of the consequences of medical, social and economic changes on an individual's life expectancy in the UK.
A thorough understanding of a longevity risk is becoming a much more important element in the underwriting of annuity risk. So the feedback from the panel will enables us to be more sophisticated in our pricing so we will be able to continue to offer our customers competitive, individually priced annuity rates in the future." John Pollock, Group Director, Legal & General Protection & Annuities
Further detail on the Longevity Science Advisory Panel is available online at http://www.longevitypanel.co.uk/
Click to the media centre for latest announcements on longevity.
Click to Legal & General's Longevity Science on the Web site
Legal & General's support for Longevity Science
Legal & General is focused on developing a better understanding of the longevity risks associated with the provision of life assurance and annuity products and services to improve the underwriting of these products in the future. So we are pleased to support the establishment of an independent panel of leading authorities who are experts on longevity issues to form, The Longevity Science Advisory Panel.
The panel is dedicated to exploring the impact that a range of factors may have on future life expectancy in the UK. This includes the drivers that are enhancing life expectancy for example, medical advances and social change, as well as the inhibitors such as lifestyle and delays in development of treatments.
As a leading annuity provider we recognised the need for an independent source to provide much needed guidance on the actual impact of the various scientific developments affecting life expectancy. There are major advancements being made in the identification and cure of many medical illnesses such as cancer, cardio-vascular and respiratory disease, which is improving how much longer we will live. However, the growth in lifestyle related problems such as diabetes is also reducing life expectancy. The establishment of the Longevity Science Advisory Panel will help us draw together an increased understanding of the consequences of medical, social and economic changes on an individual's life expectancy in the UK.
A thorough understanding of a longevity risk is becoming a much more important element in the underwriting of annuity risk. So the feedback from the panel will enables us to be more sophisticated in our pricing so we will be able to continue to offer our customers competitive, individually priced annuity rates in the future." John Pollock, Group Director, Legal & General Protection & Annuities
Further detail on the Longevity Science Advisory Panel is available online at http://www.longevitypanel.co.uk/
Click to the media centre for latest announcements on longevity.
Click to Legal & General's Longevity Science on the Web site
As a leading annuity provider we recognised the need for an independent source to provide much needed guidance on the actual impact of the various scientific developments affecting life expectancy. There are major advancements being made in the identification and cure of many medical illnesses such as cancer, cardio-vascular and respiratory disease, which is improving how much longer we will live. However, the growth in lifestyle related problems such as diabetes is also reducing life expectancy. The establishment of the Longevity Science Advisory Panel will help us draw together an increased understanding of the consequences of medical, social and economic changes on an individual's life expectancy in the UK.
A thorough understanding of a longevity risk is becoming a much more important element in the underwriting of annuity risk. So the feedback from the panel will enables us to be more sophisticated in our pricing so we will be able to continue to offer our customers competitive, individually priced annuity rates in the future." John Pollock, Group Director, Legal & General Protection & Annuities
Further detail on the Longevity Science Advisory Panel is available online at http://www.longevitypanel.co.uk/
Click to the media centre for latest announcements on longevity.
Click to Legal & General's Longevity Science on the Web site
Legal & General Group Plc. Registered in England. Registered Number: 1417162. Registered Office: One Coleman Street, London EC2R 5AA. Legal & General Group Plc is a holding company, subsidiary undertakings of which are fully authorised as appropriate under the Financial Services and Markets Act in respect of their investment activities in the UK.
© Legal & General Group Plc 2010